QuellTX
John Michael Owers, MSc RSci MRSB, has a diverse work experience spanning over a decade. John Michael began their career in 2006 as a Midshipman in the Royal Navy, where they served until 2010. From 2011 to 2015, they held various roles in customer service, sales, and hospitality at companies such as St Brelade's Bay Hotel, Geoban SA, and Santander UK.
In 2015, John transitioned into the field of scientific research, working as a Researcher at Demuris Ltd. John Michael then joined Leica Biosystems in 2016, where they held positions as a QC Scientific Officer, Tissue Acquisition Coordinator, and Scientist until 2019.
From 2019 to 2020, John worked as a Senior Production Scientist at Autolus Ltd. In 2020, they joined Quell Therapeutics, starting as a Principal Scientist in cGMP Manufacturing and later transitioning to the role of Associate Director of Manufacturing Operations.
Throughout their career, John has showcased their expertise in manufacturing operations, cGMP, tissue acquisition, and scientific research. Their work experience demonstrates their versatility and adaptability across industries, including pharmaceuticals, biotechnology, and scientific research.
John Michael Owers, MSc RSci MRSB, has a comprehensive education background in the field of science. John Michael began their academic journey in 2009 at Northumbria University, where they pursued a Bachelor of Science (BSc) degree in Biology and Forensic Biology. This three-year program lasted until 2012, equipping John with a strong foundation in the biological sciences.
Driven by their passion for biotechnology, John then embarked on a Master's degree at Newcastle University from 2014 to 2015. During this time, they successfully completed the Master of Science (MSc) program in Industrial and Commercial Biotechnology. This course provided him with specialized knowledge and skills in the industrial applications of biotechnology, preparing him for a career in this cutting-edge field.
John Michael Owers' education history demonstrates their dedication to scientific studies and their commitment to acquiring both broad and specialized knowledge in the field of biology and biotechnology. With their Bachelor's and Master's degrees, they possess a strong academic foundation and the necessary qualifications to excel in their chosen field.
This person is not in the org chart
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.